The Latest in Respiratory Care & Innovation
Stay informed with the latest news, research, and product updates from Monaghan Medical. Our commitment to advancing respiratory care drives us to develop innovative aerosol drug delivery devices and asthma management solutions that improve patient outcomes. Here, you’ll find expert insights, clinical studies, and industry updates to help healthcare professionals and patients stay ahead in respiratory health. Explore our news articles to learn about breakthrough technologies, upcoming events, and Monaghan Medical’s contributions to the future of respiratory care.
MONAGHAN MEDICAL WINS 2024 AARC ZENITH AWARD
Respiratory Care Leader Honored for Excellence in Products and Services [PLATTSBURGH, NY | October 3, 2024 - Monaghan Medical Corp., an innovator in the development and manufacturing of respiratory devices, proudly announces its recognition as a recipient of the prestigious 2024 Zenith Award, presented by the American Association for Respiratory Care (AARC). This accolade reaffirms Monaghan...
Monaghan Medical Corporation Opens New State-of-the-Art Manufacturing Facility in Plattsburgh, New York
New headquarters building doubles the operational size and is designed to place workers’ safety first during the COVID-19 pandemic PLATTSBURGH, NY (November 5, 2020) – Monaghan Medical Corporation (MMC) today announced the opening of a new 65,000-square-foot facility that doubles the size of its previous headquarters building. The new facility will house Monaghan Medical’s warehouse, […]
Read the post:Monaghan Medical Corporation Opens New State-of-the-Art Manufacturing Facility in Plattsburgh, New YorkMonaghan Medical Corporation signs a Letter of Intent to enter into US sales agreement with Adherium, a global leader in digital respiratory health technologies
PLATTSBURGH, NY – 29 April 2020: Monaghan Medical Corporation today announced it has signed a letter of intent to enter into a sales agreement with Adherium Limited (ASX:ADR), a provider of digital health solutions for remote monitoring and data management. The partnership will combine Monaghan’s knowledge and expertise in improving patient outcomes through innovative respiratory […]
Read the post:Monaghan Medical Corporation signs a Letter of Intent to enter into US sales agreement with Adherium, a global leader in digital respiratory health technologiesMonaghan Medical Corporation Announces FDA Clearance for New Respiratory Treatment Option
Monaghan Medical Corporation (MMC) today announced the newly approved combination for two of its groundbreaking products—the Aerobika® oscillatory positive expiratory pressure (OPEP) device and the VersaPAP® positive airway pressure device—to create a low cost, safe and effective “tandem therapy”.
Read the post:Monaghan Medical Corporation Announces FDA Clearance for New Respiratory Treatment OptionMonaghan Medical Corporation Wins Prestigious Zenith Award from the American Association of Respiratory Care
Award recognizes MMC’s outstanding respiratory products and services, and commitment to excellence.
Read the post:Monaghan Medical Corporation Wins Prestigious Zenith Award from the American Association of Respiratory CareMonaghan Medical Corporation Introduces an Intermediate-Size Mask
Anatomically designed mask will assist millions of Americans suffering from chronic lung disease PLATTSBURGH, NY (June 5, 2019) – Monaghan Medical Corporation (MMC) today introduced new product enhancements to continue their mission to ensure device quality for patients. Close to 50 million Americans suffer from asthma[i] or chronic obstructive pulmonary disease (COPD)[ii]—lung conditions that seriously […]
Read the post:Monaghan Medical Corporation Introduces an Intermediate-Size MaskNew published evidence reinforces the importance of device choice in asthma control
Two new publications build on previous evidence that not all devices are equally effective in delivering asthma control. PLATTSBURGH, N.Y., Jan. 31, 2018 — A recent article in Pulmonary Pharmacology and Physiology1 provides in vitro evidence that the AEROCHAMBER PLUS® FLOW-VU® valved holding chamber (or spacer) delivers aerosolized drug more effectively than other chambers, a […]
Read the post:New published evidence reinforces the importance of device choice in asthma controlSignificant reductions in costly pulmonary complications with use of drug-free device
Post-operative pulmonary complications (PPCs) are a major burden to the healthcare system. A new real-world study published in Pulmonary Therapy, indicates significant reductions in costs when using the AEROBIKA® oscillating positive expiratory pressure (OPEP) device in the postoperative care setting.1 The retrospective database analysis including 288 patients undergoing cardiac, thoracic or upper abdominal surgery suggests that use […]
Read the post:Significant reductions in costly pulmonary complications with use of drug-free deviceMonaghan’s drug-free Aerobika® device helps reduce the real-world impact of exacerbations in chronic obstructive pulmonary disease
SYRACUSE, NY, 21 February, 2017 – Monaghan Medical Corporation (MMC) today announced the publication of a study in Pulmonary Therapy showing treatment with the Aerobika® device can significantly reduce the recurrence of exacerbations of COPD in the crucial 30-day period following hospitalization or emergency room visits.1 The study also showed that per-patient cost of exacerbations was significantly lower in the […]
Read the post:Monaghan’s drug-free Aerobika® device helps reduce the real-world impact of exacerbations in chronic obstructive pulmonary diseaseNew Study Shows Monaghan Medical’s Drug-Free Aerobika® Device Shows Promise for Treatment of Bronchiectasis
SYRACUSE, NY, January 12, 2017 – Monaghan Medical Corporation (MMC) today announced that the findings of a study published in the most recent issue of Academic Radiology shows that patients with non-cystic fibrosis (CF) bronchiectasis responded favorably to airway maintenance therapy using the Aerobika® device. This latest study adds to the growing base of evidence that demonstrates Monaghan’s […]
Read the post:New Study Shows Monaghan Medical’s Drug-Free Aerobika® Device Shows Promise for Treatment of BronchiectasisNew Study Shows Monaghan Medical’s Drug-Free Aerobika® Device Reduces Acute Drug Usage And Costs Following COPD Exacerbations
Real-world study presented at CHEST 2016 Annual Meeting in Los Angeles SYRACUSE, NY, October 27, 2016 – Monaghan Medical Corporation (MMC) today announced that a new study presented to the American College of Chest Physicians (CHEST) shows MMC’s Aerobika® device is effective in reducing drug use for treatment of Chronic Obstructive Pulmonary Disease (COPD). COPD is a […]
Read the post:New Study Shows Monaghan Medical’s Drug-Free Aerobika® Device Reduces Acute Drug Usage And Costs Following COPD Exacerbations